PG电子·(中国)官方网站

News & Trends

• 212020-09

  Salubris's new drug for chronic heart failure, SAL007,was approved for clinical trial in China

  SAL007 is expected to provide a new choice for the treatment of chronic heart failure, and bring new hope to the extensive patients with chronic heart failure.

• 032020-09

  Salubris introduced Carlyle strategic investment

  Recently, CA Roam Holdings, an affiliated company of Carlyle Asia Phase V Fund under The Carlyle Group, a global investment company, invested USD 260 million to purchase about 5% of the total share capital of Salubris.

• 022020-09

  Enarodustat Tablets, a blockbuster drug for curing renal anemia, was approved for clinical use in China

  In August 2020, Salubris received the Notice of Approval of Clinical Trials from National Medical Products Administration, and initiated human clinical trials.

• 242020-07

  Super! MAURORA ® Rapamycin drug-eluting vertebral artery stent system was approved for market launch

  Recently, Alain Medical (Beijing) Co., Ltd. (hereinafter referred to as "Alain Medical ") received the Medical Device Registration Certificate approved and issued by National Medical Products Administration, and the MAURORA ® Rapamycin drug-eluting v

• 242020-02

  SalubrisBio obtained the clinical approval by FDA for a new drug SAL007 with the treatment of chronic heart failure

  Salubris Biotherapeutics, Inc., (hereinafter referred to as "SalubrisBio"), as a wholly owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd., submitted a clinical application for SAL007 to FDA on January 23, 2020, and was successfully appro

• 082020-01

  Salubris obtained the exclusive license for the super innovative product with the treatment of renal anemia

  On December 25, 2019, Salubris formally signed an agreement with Japan's JAPAN TOBACCO INC. (hereinafter referred to as "JT") at its headquarters in Shenzhen